MEDICO-ECONOMIC APPROACH FOR MIDLINE CATHETERS

COMPARATIVE STUDY:
MIDLINES VERSUS PICC LINES

Dr. Herve ROSAY,

Anaesthetist, Leon Berard Cancer Center, Lyon, France

Dr. Mostafa EL HAJJAM,

Radiologist, France, Ambroise Paré, Paris, France

Mrs. Elise METO,

Economist, REES, France







LINKS OF INTEREST





Dr ROSAY

- BD
- VYGON



Mme METO

- CNAM
- VYGON




Dr EL HAJJAM

VYGON

DIFFERENT DEVICES: PERIPHERAL INFUSATE COMPATIBLE







PERIPHERAL INFUSATE COMPATIBLE

CHOOSING THE BEST CATHETER IS DIFFICULT


- Treatment compatible.
- Length of treatment
- Complications
- Nuanced guidelines




PERIPHERAL INFUSATE COMPATIBLE



GAVECELT





PERIPHERAL INFUSATE COMPATIBLE

Figure 3. Venous access device recommendations for infusion of peripherally compatible infusate.

	Proposed Duration of Infusion					
Device Type	≤5 d	6–14 d	15–30 d	≥31 d		
Peripheral IV catheter	No preference between peripheral IV and US-guided peripheral IV catheters for use s5 d					
US-guided peripheral IV catheter	US-guided peripheral IV cathe catheter if proposed					
Nontunneled/acute central venous catheter	Central venous catheter preferred in critically ill patients or if hemodynamic monitoring is needed for 6–14 d					
Midline catheter	Midline catheter preferred to PICC if proposed duration is ≤14 d					
PICC		PICC preferred to midl	ine catheter if proposed duration o	rf infusion is ≥15 d		
Tunneled catheter				PICC preferred to tunneled catheter and ports for		
Port				infusion 15–30 d		



PROTOCOLE MICHIGAN USA

Annals of Internal Medicine

SUPPLEMENT

The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC): Results From a Multispecialty Panel Using the RAND/UCLA Appropriateness Method

Vineet Chopra, MD, MSc; Scott A. Flanders, MD; Sanjay Saint, MD, MPH; Scott C. Woller, MD; Naomi P. O'Grady, MD; Nasia Sardar, MD, PhD; Scott O. Trerotola, MD; Rajiv Saran, MD, PhD; Nancy Moureau, BSN, RN; Stephen Wiseman, PharmD; Mauro Pittiruti, MD; Elie A. Akl, MD, MPH, PhD; Agner Y. Lee, MD, MSc; Anthony Courey, MD; Lakshmi Swaminathan, MD; Jack LeDonne, MD; Carol Becker, MHSA; Sarah L. Krein, PhD, RN; and Steven J. Bernstein, MD, MPH

Putting patients first

17/10/2022

CDC 2011



Patient requiring 6 or more days of IV therapy should be assessed PICC or midline. (Category 1B)

Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011


INS 2021

Patient requiring 6-14 days of IV therapy should be assessed for a midline. For those requiring more 14 days consider CVC; Midline may remain appropriate (\$74-6)

SF2H 2013-2019

Toutes disciplines confondues, un PICC ou un midline peuvent être proposés dès qu'un abord veineux fiable d'une durée attendue supérieure ou égale à 7 j consécutifs est nécessaire (à la place d'un accès périphérique) (AF)









IS MEDICO-ECONOMIC APPROACH ABLE TO HELP THE PHYSICIAN TO CHOOSE THE GOOD CATHETER?

Not only the price of devices
But the cost of placement, the costs of complications







Duration of the		Catheter	•	Indication	
therapy (days)	PIV	Midline	PICC	mulcation	
7	V	V		Peritonitis	
14	~	V	✓	Cystic fibrosis	
21		V	~	Meningitis	

Cost of device, cost of placement. Cost of complications:

Treatment, Replacement of the device, Nursing time, Length of stay...





METHODS





STRUCTURE OF THE STUDY




Economic assessment	Budget impact analysis (only cost)		
Perspective Hospital perspective		ive	
Decision modeling	odeling Decision trees		
Time horizon	Cross section		
Comparators (devices)	PIV – Midline – PICC		
Length of treatment (days)	7	14	21
Length of treatment (days)	Peritonitis	Cystic fibrosis	Meningitis





MODEL INPUT PARAMETERS - COST VALUATION









MODEL INPUT PARAMETERS - OCCURRENCE OF COMPLICATIONS (FREQUENCIES FROM A LITERATURE REVIEW)



Complications Catheters	PIV	Midline	PICC
Systemic complications			
Thrombosis	12,50% (Elia 2012)	4,10% (Tripathi 2021)	1,50% (Swaminathan 2021)
Bloodstream infection	0,1% (Maki 2006)	0,4% (Maki 2006)	1,8% (Swaminathan 2021)
Pulmonary embolism	0%	1,65% (Bahl 2019)	0,2% (Swaminathan 2021)
Mechanical complications			
Dislodgment	7,30% (Helm 2015)	5% (Tripathi 2021)	1,50% (Piredda 2020)
Infiltration	32% (Rickard 2012)	1,9% (Tripathi 2021)	0% (Xu 2020)
Catheter occlusion	22,80% (Helm 2015)	3,8% (Tripathi 2021)	5,8% (Swaminathan 2021)







RESULTS





MIDLINE VS PIV: 7-DAY TREATMENT



		COST PER T & PER PERIOD	INCREMENTAL COST	
	MIDLINE	PIV	MIDLINE vs PIV	
Micro-costing				
Consumables	€32,63	€5,40	€27,23	
Device	€60,19	€1,94	€58,25	
Clinicians & Nurses time	€42,42	€42,68	- €0,27	
Paramedical exams	€15,76	€0,00	€15,76	
Mechanical complications	€11,09	€37,35	- €26,25	
Micro-costing total (1)	€162,09	€87,38	+ €74,71	
DRG Cost				
Ex : medical indication peritonitis	€3 679,18	€3 679,18	€0,00	
Systemic complications	€41,32	€239,99	- €198,67	
Total DRG Cost (II)	€3 720,50	€3 919,17	- €198,67	
Net Medical Cost (I)+(II)	€3 881,94	€4 006,31	- €123,95	





MIDLINE VS PIV VS PICC: 14-DAY TREATMENT



	ESTIMATED COST PER PATIENT & PER PERIOD			INCREMENTA	AL COST
	MIDLINE	PIV	PICC	MIDLINE vs PIV	MIDLINE vs PICC
Micro-costing					
Consumables	€45,66	€8,39	€45,71	€37,27	- €0,05
Device	€60,19	€3,02	€66,28	€57,17	- €6,09
Clinicians & Nurses time	€78,36	<i>€75,45</i>	€93,08	€2,92	- €14,71
Paramedical exams	€15,76	€0,00	€49,69	€15,76	- €33,93
Mechanical complications	€22,42	€ 59,35	€23,06	- €36,92	- €0,64
Micro-costing total (I)	€222,39	€146,20	€277,81	+ €76,20	- €55,42
DRG Cost					
Ex : medical indication Cystic fibrosis	€10 775,16	€10 775,16	€10 775,16	€0,00	€0,00
Systemic complications	€80,86	€368,84	€62,48	-€287,97	€18,38
Total DRG Cost (II)	€10 856,02	€11 144	€10 837,64	-€287,97	+€18,38
Grand GENERAL (I)+(II)	€11 078,42	€11 290,20	€11 115,46	- €211,78	- €37,04





MIDLINE VS PICC: 21-DAY TREATMENT



	ESTIMATED COST PER PA PERIO	INCREMENTAL COST	
	MIDLINE PICC		MIDLINE vs PICC
Micro-costing			
Consumables	€58,69	€58,73	- €0,04
Device	€60,19	€66,28	- €6,09
Clinicians & Nurses time	€114,31	€128,99	- €14,68
Paramedical exams	€15,76	€49,69	- €33,93
Mechanical complications	€25,60	€23,30	€2,30
Micro-costing total (1)	€274,55	€327	- €52,45
DRG Cost			
Ex : medical indication meningitis	€9 286,52	€9 286,52	€0,00
Systemic complications	€94,23	€62,48	€31,75
Total DRG Cost (II)	€9 380,75	€9 349	+ €31,75
Grand GENERAL (I)+(II)	€9 655,30	€9 676	- €20,70





CONCLUSIONS



Midline is cheaper!

7 days	14 days		21 days
PIV: - € 124	PIV: - € 212	PICC: - € 37	PICC: - € 21




CONCLUSION AND DISCUSSION



- Medico economic approach cannot and must not decide the choice of a medical device. However, in a strained economic context, this approach is important and can help the physician's choice
- Despite a price 93 times higher than PIV, Midline is greatly cheaper than PIV for 7 and 14 days treatments. Because of the rates and costs of complications, and mainly with the induced time-consuming of nurses and operators.
- Costs of Midlines and Picc-Lines for 14 and 21 days treatments are similar, lightly in favor on midline in this model.
- This model can be discussed and results can differ between other hospitals. Prices of consumables, type of operators and methods of tip placement, rate of complications could influence results



Correct choice of the Catheter



Pertinence d'une équipe cathéters en court séjour auprès des personnes âgées - 25/08/20

Relevance of a catheter team for short stays with elderly people

Doi: 10.1016/j.sger.2020.03.007

Aurélie Todeschi ^a, _a: Infirmière, Xavier Dupont ^b: Praticien hospitalier, Nathalie Barral ^b: Praticien hospitalier, Sabine Gnamien ^c: Praticien hospitalier, Marie-Christine Gramer ^d: Cadre supérieur de santé, Florence Espinasse ^d: Praticien hospitalier, Mostafa El Hajjam ^e: Praticien hospitalier













THANK YOU FOR YOUR ATTENTION





CONCLUSION



Paloma RUIZ, VA Nurse, MSc, PhD, Hospital Severo Ochoa, Madrid, Spain

Speakers contact details

- PICC port: When patient safety meets the patient's lifestyle
 - Dr. Fulvio PINELLI: fulvio.pinelli@me.com
- Non coring needle: How to combine nurse needs with patient's comfort
 - Mr. Christian DUPONT: christian.dupont@aphp.fr
- Midline: Is there a place for midlines among other VAD in a strained economic context? Introduction of a new medico-economic study
 - Dr. Hervé ROSAY: herve.rosay@lyon.unicancer.fr
 - Mrs. Elise METO: *emeto.reesfrance@orange.fr*
 - Dr. Mostafa EL HAJJAM: *mostafa.elhajjam@aphp.fr*



THANK YOU!

PUTTING PATIENTS FIRST:
ENHANCING VASCULAR
ACCESS PRACTICES IN
STRAINED ECONOMIC
SITUATIONS





